What is really exciting about this technology is its ability to treat a broad range of applications utilizing only one device.
Wausau, WI (PRWEB) April 13, 2016
Paul M. Friedman, MD was awarded the Best of Cutaneous Applications Abstract Session Award for his abstract titled, “TRASER: Preliminary Results from a Clinical Trial for the Treatment of Nasal Telangiectasias,” which was presented during the Cutaneous Applications session at the 2016 Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS) held in Boston.
"It is quite an honor to receive the award. I previously served as an ASLMS Annual Conference session co-chair for two years and program co-chair last year,” said Friedman. “I know the hundreds of excellent scientific abstracts that are submitted each year, so to be chosen as the best is very humbling.”
The abstract presents clinical research on an investigational technology called TRASER, a fluorescent-based optical device which is unique because it is tunable. A narrow spectrum of light can be configured with the ability to provide a wide range of parameters based on the condition that is targeted. TRASER stands for Total Reflection Amplification of Spontaneous Emission of Radiation.
“What is really exciting about this technology is its ability to treat a broad range of applications utilizing only one device,” said Friedman. “In our study, we looked at nasal telangiectasias, which are notoriously difficult to treat, and found greater than 75% improvement after one and three-month follow-up.”
Dr. Friedman has been recognized as a leading physician and researcher in the field and also been involved in the development of several new laser systems and therapeutic techniques now commonly used throughout the world. Board-certified by the American Board of Dermatology, he is the director of Dermatology & Laser Surgery Center of Houston, Texas, and also practices at the Laser & Skin Surgery Center of New York. Dr. Friedman is a clinical assistant professor at the University of Texas Medical School, department of dermatology, and a clinical assistant professor of dermatology at the Weill Cornell Medical College, Houston Methodist Hospital. He is also on staff at Texas Children's Hospital and Memorial-Hermann Hospital-Texas Medical Center.
Elizabeth R.C. Geddes, MD, a dermatologist in practice with Dr. Friedman at the Dermatology & Laser Surgery Center in Houston, presented the study at the conference. “TRASER is a new device. It is not a laser and it is not an IPL (Intense Pulsed Light device),” said Geddes. “We are excited about this technology. Since it offers the unique characteristic of being able to tune a very narrow spectrum of wavelength anywhere in the visible light range, we are able to treat a number of conditions very efficiently.”
The Annual Conference of the American Society for Laser Medicine & Surgery, Inc. is regarded as the top meeting for the exchange of information on the latest discoveries, applications and research involving medical lasers and energy based devices. 2016 marks the 36th year of the ASLMS Annual Conference. Visit aslms.org for more information.